Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ischemic

Prior to this work, dietary fiber, of which ceUulose is oae of the more important constituents, was considered important primarily as a means of preventing or overcoming constipation. Otherwise, dietary fiber was considered to be a metaboHcally iaert substance. A large variety of diseases such as appendicitis, hiatus hernia, gallstones, ischemic heart disease, diabetes, obesity, dental caries, and duodenal ulcers are now suspected to be associated with the consumption of a highly refined diet (42). [Pg.353]

Nuclear medicine studies may reveal information that is primarily anatomic in nature, or indicate the function of an organ on a regional basis (Table 1). These studies may be intended to identify new disease, confirm or deny suspected disease, or foUow the progress of treatment or the course of disease. The diseases may be relatively benign or extremely serious and can range from widespread medical problems such as ischemic heart disease to rarities such as Legge-Perthe s disease and malignant pheochromocytoma (7). [Pg.474]

Technetium-9 9m sestamibi is used in myocardial perfusion imaging for the evaluation of ischemic heart disease. It is prepared from a lyophilized kit containing tetrakis(2-methoxy isobutyl isonittile) copper(I) tetrafluoroborate stored under nitrogen. Upon reconstitution with up to 5.6 GBq (150 mCi) of 99mTc pertechnetate, the product is formed by boiling for 10 minutes. [Pg.483]

Homocysteine arises from dietary methionine. High levels of homocysteiae (hyperhomocysteinemia) are a risk factor for occlusive vascular diseases including atherosclerosis and thrombosis (81—84). In a controlled study, semm folate concentrations of <9.2 nmol/L were linked with elevated levels of plasma homocysteiae. Elevated homocysteine levels have beea associated also with ischemic stroke (9). The mechanism by which high levels of homocysteine produce vascular damage are, as of yet, aot completely uaderstood. lateractioa of homocysteiae with platelets or eadothehal cells has beea proposed as a possible mechanism. Clinically, homocysteine levels can be lowered by administration of vitamin B, vitamin B 2> foHc acid. [Pg.42]

Glass IB Antiarrhythmic Agents. Class IB antiarrhythmic agents produce less inhibition of the inward sodium current than Class lA agents. In normal myocardial tissue, phase 0 may be unaffected or minimally depressed. However, in ischemic or infarcted tissue, phase 0 is depressed. Myocardial tissue exposed to Class IB agents exhibits decreased automaticity, shortened action potential duration, ie, shortened repolarization, and shortened refractory period. Excitability of the myocardium is not affected and conduction velocity is increased or not modified. The refractory period is shortened less than its action potential duration, thus the ratio of refractory period to action potential duration is increased by these agents. The net effect is increased refractoriness. The PR and QT intervals of the ECG are shortened and the QRS interval is unchanged (1,2). [Pg.113]

A third study (85) enrolled 7825 hypertensive patients (55% males and 45% females) having diastoHc blood pressures (DBP) of 99—104 mm Hg (13—14 Pa) there were no placebo controls. Forty-six percent of the patients were assigned to SC antihypertensive dmg therapy, ie, step 1, chlorthaUdone step 2, reserpine [50-55-5] or methyldopa [555-30-6], and step 3, hydralazine [86-54-4]. Fifty-four percent of the patients were assigned to the usual care (UC) sources in the community. Significant reductions in DBP and in cardiovascular and noncardiovascular deaths were noted in both groups. In the SC group, deaths from ischemic heart disease increased 9%, and deaths from coronary heart disease (CHD) and acute myocardial infarctions were reduced 20 and 46%, respectively. [Pg.212]

Nowadays the one of the leading cause of death in industrial country is Heart Failure (HF). Under the pathological conditions (e.g., Ischemic Heart Disease (IHD)) the changes in the enzymes activity and ultrastructure of tissue were obtained. The behavior of trace elements may reflect the activity of different types of enzymes. Pathological changes affects only small area of tissue, hence the amount of samples is strictly limited. Thereby, nondestructive multielemental method SRXRF allow to perfonu the analysis of mass samples in a few milligrams, to save the samples, to investigate the elemental distribution on the sample area. [Pg.353]

Wackerhage, H., Mneller, K., Hoffmann, U., et al., 1996. Glycolytic ATP production estimated from "" P magnetic resonance spectroscopy measurements during ischemic exercise in vivo. 4 151-155. [Pg.638]

Linz W, Martorana PA, Scholkens B (1990) Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Parmacol 15 S99-S109... [Pg.11]

The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 1464-1476... [Pg.112]

Arteriogenesis is the growth of collateral vessels from a pre-existing arteriolar network to bypass an ischemic area (e.g., following cardiac ischemia). [Pg.222]

Myocardial infarcts Ca2+ homeostasis is lost in ischemic areas, triggering inappropriate calpain activity. Desmin and a-spectrin are degraded in ischemic hearts by synthetic calpain inhibitors. Protein and mRNA levels of m and (./-calpain increase after myocardial infarction40-43... [Pg.313]

Neuronal ischemia Calpastatin is degraded by calpain to a membrane-bound 50-kDa polypeptide in ischemic... [Pg.313]

An amiloride analog that inhibits Na+/H+ ion exchangers and is under consideration for the prevention of post-ischemic damage. [Pg.328]

Traumatic brain injury is the most common cause of death in subjects under the age of 40, and an important risk factor for AD. Loss of hippocampal cells and depletion of ACh and of muscarinic receptors can be attenuated in injured experimental animals, improve blood perfusion in ischemic areas and increase cholinergic transmission in cortex and hippocampus the same mechanism invoked for treatment of VD. [Pg.360]

S-0139 Shionogi/GSK, Japan ETA receptor Hemorrhagic and ischemic stroke (phase II, Japan)... [Pg.476]


See other pages where Ischemic is mentioned: [Pg.353]    [Pg.539]    [Pg.171]    [Pg.485]    [Pg.122]    [Pg.123]    [Pg.143]    [Pg.212]    [Pg.312]    [Pg.533]    [Pg.96]    [Pg.85]    [Pg.121]    [Pg.261]    [Pg.296]    [Pg.316]    [Pg.302]    [Pg.227]    [Pg.20]    [Pg.20]    [Pg.79]    [Pg.84]    [Pg.170]    [Pg.205]    [Pg.207]    [Pg.224]    [Pg.313]    [Pg.323]    [Pg.333]    [Pg.402]    [Pg.424]    [Pg.454]    [Pg.574]    [Pg.664]    [Pg.665]   
See also in sourсe #XX -- [ Pg.29 , Pg.30 , Pg.47 , Pg.53 , Pg.57 , Pg.58 , Pg.101 ]

See also in sourсe #XX -- [ Pg.74 , Pg.84 ]

See also in sourсe #XX -- [ Pg.207 , Pg.213 , Pg.214 ]

See also in sourсe #XX -- [ Pg.1460 ]




SEARCH



AND ISCHEMIC PRECONDITIONING

Acute Ischemic Stroke: An Evidence-based Approach, Edited by David M. Greer

Acute cerebral ischemia ischemic penumbra

Acute coronary syndromes Ischemic heart disease

Acute ischemic stroke

Acute ischemic stroke endovascular cooling

Acute ischemic stroke mild hypothermia

Acute treatment of transient ischemic attack and minor stroke

Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic

Amlodipine in ischemic heart disease

Animal models ischemic injury

Anti-ischemic agents

Apoptosis ischemic

Attenuation of Ischemic Brain Damage by Aged Garlic Extracts

Beta-adrenergic preconditioning ischemic

Brain imaging in transient ischemic attack and minor stroke

Brain injury, hypoxic-ischemic

Brain ischemic

Calcium channel blockers in ischemic heart disease

Cardiac ischemic complications, prevention

Cardiovascular disorders ischemic heart disease

Carotid artery atherosclerosis, ischemic

Carotid artery atherosclerosis, ischemic stroke

Causes of TIA and ischemic

Causes of TIA and ischemic stroke

Cell transplantation ischemic heart disease

Cerebral edema, cytotoxic ischemic

Cerebral ischemic infarction

Cerebrovascular disorders ischemic

Chronic ischemic heart disease

Chronic ischemic heart disease acute coronary syndromes

Chronic ischemic heart disease exercise

Chronic ischemic heart disease, effects

Clinical ischemic penumbra

Clinical trials ischemic stroke

Complications ischemic

Cytotoxic ischemic cerebral

DEDAS ischemic stroke

Damage ischemic

Defibrillators in non-ischemic

Desmoteplase in acute ischemic stroke

Diltiazem in ischemic heart disease

Dipyridamole transient ischemic attacks

Elderly ischemic heart disease

Embolism ischemic stroke

Glutamate in Ischemic Injury

Heart disease ischemic

Hepatic disease ischemic hepatitis

Hypertension ischemic heart disease and

Hypothermia acute ischemic stroke

Hypoxic-ischemic encephalopathy

Intra-arterial thrombolysis for acute ischemic

Ischemia disorders, ischemic

Ischemic Cells

Ischemic Stroke Basic Pathophysiology and Neuroprotective Strategies

Ischemic acidosis

Ischemic acute renal failure

Ischemic attack

Ischemic brain injury

Ischemic brain tissue

Ischemic cardiac myocytes

Ischemic cardiomyopathy

Ischemic cascade

Ischemic cerebral edema

Ischemic change imaging

Ischemic colitis

Ischemic colitis therapy

Ischemic conditions

Ischemic contracture

Ischemic core

Ischemic disease

Ischemic dysfunction

Ischemic events

Ischemic functional impairments

Ischemic heart disease 1630 INDEX

Ischemic heart disease Myocardial infarction

Ischemic heart disease alterable

Ischemic heart disease and

Ischemic heart disease arrhythmia

Ischemic heart disease aspirin

Ischemic heart disease assessment

Ischemic heart disease beta-blockers

Ischemic heart disease calcium channel blockers

Ischemic heart disease case study

Ischemic heart disease clinical presentation

Ischemic heart disease coronary angiography

Ischemic heart disease coronary blood flow

Ischemic heart disease diagnosis

Ischemic heart disease electrocardiogram

Ischemic heart disease epidemiology

Ischemic heart disease etiology

Ischemic heart disease evaluation

Ischemic heart disease gene therapy

Ischemic heart disease goals

Ischemic heart disease homocysteine

Ischemic heart disease nitrates

Ischemic heart disease nitroglycerin

Ischemic heart disease oxygen demand

Ischemic heart disease pathophysiology

Ischemic heart disease silent ischemia

Ischemic heart disease statins

Ischemic heart disease syndrome

Ischemic heart disease syndromes Angina pectoris

Ischemic heart disease therapeutic angiogenesis

Ischemic heart disease treatment

Ischemic hepatitis

Ischemic hypoxia

Ischemic infarction

Ischemic injury

Ischemic injury glutamate-mediated

Ischemic liver damage

Ischemic myocardial changes

Ischemic myocardial dysfunction

Ischemic myocardium

Ischemic myopathy

Ischemic neuronal death

Ischemic neuropathy

Ischemic penumbra

Ischemic penumbra perfusion-weighted

Ischemic preconditioning

Ischemic preconditioning delayed

Ischemic preconditioning signal transduction

Ischemic region

Ischemic reperfusion

Ischemic retinal diseases

Ischemic retinopathies

Ischemic stricture

Ischemic stroke

Ischemic stroke clopidogrel

Ischemic stroke diagnosis

Ischemic stroke etiology

Ischemic stroke incidence

Ischemic stroke pathophysiology

Ischemic stroke prevention

Ischemic stroke therapies

Ischemic stroke treatment

Ischemic tissue

Ischemic tolerance

Ischemic ulcers

Ischemic/reperfusion model

Kuopio ischemic heart disease risk factor

Large artery disease, cause ischemic stroke

Liver disease ischemic hepatitis

Long Term Intervention with Pravastatin in Ischemic

Long-term prognosis after transient ischemic attack and stroke

Lower ischemic complications

Major ischemic stroke

Mechanism of Neuroprotection in Ischemic Injury

Myelomalacia acute ischemic

Myocardial infarction coronary syndromes Ischemic heart disease

NMDA antagonists ischemic injury

Neurochemical Aspects of Ischemic Injury

Nifedipine in ischemic heart disease

Nitrates in ischemic heart disease

Non-radiological investigations for transient ischemic attack and stroke

Nonarteritic anterior ischemic optic neuropathy

Of ischemic heart disease

Operational ischemic penumbra

Optic neuropathy anterior ischemic

Potential Neuroprotective Strategies for Ischemic Injury

Potential Treatment Strategies for Ischemic Injuries

Pravastatin Ischemic Disease) study

Priapism ischemic

Protective effect of PBN on ischemic-reperfused myocardium

Retinal ischemic injury

Short-term prognosis after transient ischemic attack and minor stroke

Spatial Memory Deficit and the Apoptotic Neuronal Death in Ischemic Rats

Specific treatments for major acute ischemic stroke

TIA and ischemic stroke

TIA and ischemic stroke syndrome

Tissue Repair and Recovery After Ischemic Stroke

Transient ischemic attack

Transient ischemic attack clopidogrel

Transient ischemic attacks, treatment

Treatment for major acute ischemic stroke

Treatment of Ischemic Stroke

Vascular imaging in transient ischemic attack and stroke

Vasogenic ischemic cerebral

Vasogenic ischemic cerebral edema

Verapamil in ischemic heart disease

Vessel ischemic disease

Warm ischemic time

© 2024 chempedia.info